| Discovery and characterization of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents S Wang, G Griffiths, CA Midgley, AL Barnett, M Cooper, J Grabarek, ... Chemistry & biology 17 (10), 1111-1121, 2010 | 121 | 2010 |
| Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202 D Gherardi, V D’Agati, THT Chu, A Barnett, A Gianella-Borradori, ... Journal of the American Society of Nephrology 15 (5), 1212-1222, 2004 | 115 | 2004 |
| Antiviral activity of CYC202 in HIV-1-infected cells E Agbottah, C de La Fuente, S Nekhai, A Barnett, A Gianella-Borradori, ... Journal of Biological Chemistry 280 (4), 3029-3042, 2005 | 100 | 2005 |
| Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection AL Barnett, RA Davey, JM Cunningham Proceedings of the National Academy of Sciences 98 (7), 4113-4118, 2001 | 98 | 2001 |
| Receptor binding transforms the surface subunit of the mammalian C-type retrovirus envelope protein from an inhibitor to an activator of fusion AL Barnett, JM Cunningham Journal of virology 75 (19), 9096-9105, 2001 | 87 | 2001 |
| Homeoproteins CDP and SATB1 interact: potential for tissue-specific regulation J Liu, A Barnett, EJ Neufeld, JP Dudley Molecular and cellular biology 19 (7), 4918-4926, 1999 | 84 | 1999 |
| Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT … RW Koivula, A Heggie, A Barnett, H Cederberg, TH Hansen, ... Diabetologia 57 (6), 1132-1142, 2014 | 75 | 2014 |
| In vitro host range of Autographa californica nucleopolyhedrovirus recombinants lacking functional p35, iap1 or iap2. CM Griffiths, AL Barnett, MD Ayres, J Windass, LA King, RD Possee Journal of General Virology 80 (4), 1055-1066, 1999 | 69 | 1999 |
| Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus AL Barnett, DL Wensel, W Li, D Fass, JM Cunningham Journal of virology 77 (4), 2717-2729, 2003 | 51 | 2003 |
| Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA) M Convertino, TR Church, GW Olsen, Y Liu, E Doyle, CR Elcombe, ... Toxicological Sciences 163 (1), 293-306, 2018 | 42 | 2018 |
| R-roscovitine (CYC202) alleviates renal cell proliferation in nephritis without aggravating podocyte injury M Milovanceva-Popovska, U Kunter, T Ostendorf, A Petermann, S Rong, ... Kidney international 67 (4), 1362-1370, 2005 | 34 | 2005 |
| Design, Synthesis, and Evaluation of 2-Methyl- and 2-Amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as Ring-Constrained 2-Anilino-4-(thiazol-5-yl … NA McIntyre, C McInnes, G Griffiths, AL Barnett, G Kontopidis, AMZ Slawin, ... Journal of medicinal chemistry 53 (5), 2136-2145, 2010 | 32 | 2010 |
| Engineered baculoviruses for pest control RD Possee, AL Barnett, RE Hawtin, LA King Pesticide Science 51 (4), 462-470, 1997 | 31 | 1997 |
| Expression of mouse mammary tumor virus superantigen mRNA in the thymus correlates with kinetics of self-reactive T-cell loss A Barnett, F Mustafa, TJ Wrona, M Lozano, JP Dudley Journal of virology 73 (8), 6634-6645, 1999 | 29 | 1999 |
| Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases RC Jackson, AL Barnett, SJ McClue, SR Green Expert opinion on drug discovery 3 (1), 131-143, 2008 | 20 | 2008 |
| A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. IR MacPherson, D Bissett, RD Petty, B Tait, LM Samuel, J MacDonald, ... Journal of Clinical Oncology 29 (15_suppl), 3063-3063, 2011 | 15 | 2011 |
| Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: human tumor xenograft efficacy and in vitro mode of … A Barnett, S Ding, C Murray, M Chamberlain, S Plummer, TRJ Evans, ... Ejc Supplements 8 (7), 45-46, 2010 | 11 | 2010 |
| Treatment with a cyclin‐dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental … AM Sheryanna, J Smith, G Bhangal, A Barnett, S McCLUE, FWK Tam, ... Nephrology 16 (4), 410-416, 2011 | 10 | 2011 |
| The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project HJA Teare, F De Masi, K Banasik, A Barnett, S Herrgard, B Jablonka, ... Life sciences, society and policy 14 (1), 20, 2018 | 8 | 2018 |
| Anti-tumor activity of CXR1002, a novel anti-cancer compound that induces ER stress: Human tumor xenograft efficacy and in vitro mode of action AL Barnett, S Ding, C Murray, DN Lee, S Plummer, TRJ Evans, ... Cancer Research 70 (8 Supplement), 3566-3566, 2010 | 2 | 2010 |
